HUE032560T2 - Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása - Google Patents

Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása Download PDF

Info

Publication number
HUE032560T2
HUE032560T2 HUE11799979A HUE11799979A HUE032560T2 HU E032560 T2 HUE032560 T2 HU E032560T2 HU E11799979 A HUE11799979 A HU E11799979A HU E11799979 A HUE11799979 A HU E11799979A HU E032560 T2 HUE032560 T2 HU E032560T2
Authority
HU
Hungary
Prior art keywords
rhdl
formulation
cholate
apo
lipid
Prior art date
Application number
HUE11799979A
Other languages
English (en)
Inventor
Samuel Wright
Martin Imboden
Reinhard Bolli
Marcel Waelchli
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of HUE032560T2 publication Critical patent/HUE032560T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (3)

  1. L IkMáöli «a&amp;y s&amp;dsegd ({rHÄ}' iâsa^rafe* ssply fspgmemdi:; 1oS:#;f«äj|>Sifoi ; és epesót vagy «p^vskMrS&amp;giii! 0,.5 -0,5 g/L köncsabráejóbaa. '$. A® 1, igôeyp»«l saerfsO dllïL a® epssô ivsgy ppesav kö8<:gh0;ác;id|g kÓiÉibelif ^ÛlSlkOlO g/g aponpopmieb'h 3< A® !. vsgy 2, ígáoyp-ösíís®snoti TBD&amp;kitoF#à§, hkd m«$&amp;sê vagy sppsav öálAapOlgiát 4, te s|l# tpnypptek Sfenelyik® sæeîàsl 11« tlUM, itomls, ahol a®/äp«!spprp«i8 vljgy IVagmense.
  2. 5, AzelOxO í|s#3^eRlöfe:BÍTOáy^«· xzersMkrHBL kls®<a'eiés, ate! föxrfo lipid fosxíaiidiitete, 4Jm <slSs«Ô ^^»îîôikMmïiî^yls« ssteki: îte rHDL ksxzemkis, ahol s kî^reldl sísfeíI®áíÖ$K«0: h tóíialma®.
  3. 7. Bgtex a kOslltetekei ïam1»^S MM·· fcisgsteés elMi&amp;hâra: agölspsprsjfcm' 4..'Κθφ;0, ^ sk?5çrge«A apply ®S|Äs magába« fegfsija m eppsd .vagy :e$J«sav iÉiiæteftèsàRsfc. láp&amp;ií kMpäÄJ' %5 :- iyS git-koneentrációban a* rHDL kisxere&amp;xbe».: W&amp; Ύ<·. :%feyp£H$i .Mái eljárás, gte! ;a® egssà vagy ppeaav kespgikrâeâôja: kOKlbsi®! 0331541,010 g/g ap;dsp;>pmtesv f), A 7. vagy 0. igényper ^irÄvllPL,kis®»rÄ’g8böf az epesd vagy Sfpss« «àtriaa^fes ÎU. A ?-9. saany-pisatok: bármelyik® s®«f1atl sljânls, als«! ä® spoOpPpiPSp*0 Apm-ÁI vagy 0'ägmense.: IL A ? If; iglnypOïsUîk bármelyik® mninl! eljárás, ab«! a Il A ·»-! \ ígétiypoalok bármelyike xaennii eljárás, amely a kövelkegáláptekei fogsslp spgábim: í A) sgpswsölíMsap' Aalköís Bxsteklíiteim es !ρ||! deíergeos hömisdáxái: Agg-AO «ÄOaso |B) a köíát deîageas · teiftÉa§^3á|Mk vsbkkegídsál a® IA) Mpéteeli teisjfe* kOslibspl40¾¾ Λρ«·Α I szi«im; |€) sisb!lisátöSK«f iKígppásái a (M lépOsibeii «Idashe®, lí .A 7- Í2. ígó«vpö«iök bármelyike aaeriöií blkbássai aldálHfeiá ríBOL khzmlés. li, a® 1·ί>· igéípptete vagy 13. igé«y|xmibáímeíyik«A®eílf0rrlB5L:k1s®»í«i«s, lPíiefs#>^^mnpilaftssség va^· álleppí: «ïfiPrb«« veié ksxefêsëten idpôkô ;0k«!ms®|sm Ili Λ 14. Igényposi sv.srhrd rl l Dl, kiszerelés alkalmazásra. ah«! a betegség, «sadeiteassseg vagy áliapsi kasdsövasíkiOáP b«íags% h?pertefei?iPfí#m&amp; vsgy:h{pök«fes2ierio®«íÍ!S. 14 Λ 15.igPppite szerints rílBL kiszerelés alkalmazásra, sises a betegség, re«Kkíls«exseg vágyállapé akui köförs# 4 sglfiikitea ;|ACi$j, afe»8®klsí®®is vagy miftkárd iáfe tóárMsp
HUE11799979A 2010-06-30 2011-06-30 Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása HUE032560T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35992510P 2010-06-30 2010-06-30

Publications (1)

Publication Number Publication Date
HUE032560T2 true HUE032560T2 (hu) 2017-09-28

Family

ID=45401226

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE11799979A HUE032560T2 (hu) 2010-06-30 2011-06-30 Feloldott nagy sûrûségû lipoprotein kiszerelés és elõállítási eljárása
HUE16203579A HUE042391T2 (hu) 2010-06-30 2011-06-30 Visszaoldott nagysûrûségû lipoprotein kiszerelés és elõállítási eljárása

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16203579A HUE042391T2 (hu) 2010-06-30 2011-06-30 Visszaoldott nagysûrûségû lipoprotein kiszerelés és elõállítási eljárása

Country Status (17)

Country Link
US (5) US8999920B2 (hu)
EP (3) EP3178481B1 (hu)
JP (2) JP5989641B2 (hu)
KR (1) KR101782309B1 (hu)
CN (2) CN105396122B (hu)
AU (1) AU2011274238B2 (hu)
CA (1) CA2803031C (hu)
DK (2) DK3178481T3 (hu)
ES (2) ES2718234T3 (hu)
HU (2) HUE032560T2 (hu)
IL (1) IL223815A (hu)
MX (1) MX2012014928A (hu)
PL (2) PL2588113T3 (hu)
SG (1) SG186386A1 (hu)
TR (1) TR201903209T4 (hu)
TW (1) TWI531388B (hu)
WO (1) WO2012000048A1 (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2588113T3 (pl) 2010-06-30 2017-06-30 Csl Limited Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
CN103833840A (zh) * 2012-11-27 2014-06-04 上海复星医药（集团）股份有限公司 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法
JP6404333B2 (ja) * 2013-06-05 2018-10-10 シーエスエル、リミテッド アポリポタンパク質ａ−ｉ（アポａ−ｉ）の製造方法
KR102437202B1 (ko) 2013-08-08 2022-08-29 시에스엘 리미티드 오염 제거 방법
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
KR101563403B1 (ko) * 2013-11-05 2015-10-26 영남대학교 산학협력단 지방물질의 안전성 평가방법
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
EP3238746B1 (en) * 2014-12-25 2023-12-20 Kyoto University High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
EP3490579A1 (en) 2016-07-27 2019-06-05 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
CN109922810A (zh) 2016-11-10 2019-06-21 杰特有限公司 心肌梗塞的重构的高密度脂蛋白治疗
CN111601614A (zh) * 2017-11-07 2020-08-28 阿尔法科制药有限责任公司 治疗和预防心脏病、心血管疾病及相关病症和症状的方法
WO2019133358A2 (en) * 2017-12-28 2019-07-04 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
KR102531293B1 (ko) * 2021-12-06 2023-05-16 (주) 멥스젠 신규한 재구축 고밀도 지단백 나노입자

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335077C (en) 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
BR0212880A (pt) 2001-09-28 2005-12-13 Esperion Therapeutics Inc Uso de uma droga moduladora de lipìdeo, kit para tratamento ou redução, stent revestido com um material a ser liberado em um local a ser tratado, e composição farmacêutica
MXPA04011312A (es) 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
BR0310100A (pt) 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
PE20050438A1 (es) 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
US20070254832A1 (en) 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CN100586958C (zh) * 2006-12-20 2010-02-03 上海莱士血液制品股份有限公司 高纯度载脂蛋白a-i的制备方法
KR100992488B1 (ko) 2006-12-29 2010-11-05 주식회사 녹십자 ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법
WO2009025754A2 (en) 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
WO2010057203A2 (en) * 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
PL2588113T3 (pl) 2010-06-30 2017-06-30 Csl Limited Odtworzona formulacja lipoproteiny o wysokiej gęstości i sposób jej produkcji
ES2717455T3 (es) 2011-02-07 2019-06-21 Cerenis Therapeutics Holding Sa Complejos de lipoproteínas y fabricación y usos de los mismos
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation

Also Published As

Publication number Publication date
CN105396122A (zh) 2016-03-16
PL2588113T3 (pl) 2017-06-30
US11723953B2 (en) 2023-08-15
EP3178481A1 (en) 2017-06-14
ES2718234T3 (es) 2019-06-28
MX2012014928A (es) 2013-03-22
TWI531388B (zh) 2016-05-01
ES2617977T3 (es) 2017-06-20
US10335457B2 (en) 2019-07-02
WO2012000048A1 (en) 2012-01-05
KR101782309B1 (ko) 2017-09-27
US20130190226A1 (en) 2013-07-25
TW201206446A (en) 2012-02-16
PL3178481T3 (pl) 2019-07-31
US20160022768A1 (en) 2016-01-28
AU2011274238A1 (en) 2013-01-17
US8999920B2 (en) 2015-04-07
SG186386A1 (en) 2013-01-30
US20170196935A1 (en) 2017-07-13
AU2011274238B2 (en) 2013-09-26
EP3178481B1 (en) 2019-01-02
KR20130100970A (ko) 2013-09-12
IL223815A (en) 2017-08-31
JP2013529648A (ja) 2013-07-22
TR201903209T4 (tr) 2019-03-21
EP2588113A1 (en) 2013-05-08
CN103118683B (zh) 2015-08-19
DK2588113T3 (en) 2017-03-20
EP3492085A1 (en) 2019-06-05
US20220133852A1 (en) 2022-05-05
EP2588113B1 (en) 2016-12-14
EP2588113A4 (en) 2014-12-03
DK3178481T3 (en) 2019-04-08
JP5989641B2 (ja) 2016-09-07
CA2803031A1 (en) 2012-01-05
CA2803031C (en) 2021-06-22
JP2016188226A (ja) 2016-11-04
HUE042391T2 (hu) 2019-06-28
US20200171126A1 (en) 2020-06-04
CN105396122B (zh) 2020-09-11
CN103118683A (zh) 2013-05-22
US11058747B2 (en) 2021-07-13
US9439946B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
US11723953B2 (en) Reconstituted high density lipoprotein formulation and production method thereof
JP5248113B2 (ja) ペプチドの安定な処方
US11957731B2 (en) Reconstituted HDL formulation
CN107753953B (zh) 聚乙二醇化激肽原酶的制剂及其应用
DK2916857T3 (en) RECONSTITUTED HDL FORMULATION